Advertisement
Prostate Cancer – Diagnosis and Staging| Volume 20, SUPPLEMENT 2, S48, October 2020

Systematic biopsy is unnecessary for the detection of clinically significant prostate cancer in men with PIRADS 5 and PSA density greater than 15%

Open AccessDOI:https://doi.org/10.1016/S2666-1683(20)35358-1
Systematic biopsy is unnecessary for the detection of clinically significant prostate cancer in men with PIRADS 5 and PSA density greater than 15%
Previous ArticleTMPRSS2: ERG expression in prostate cancer: Imaging and clinico-pathological correlations
Next ArticleUpstaging after radical prostatectomy in clinically localized intermediate and high-risk prostate cancer: The role of obesity
      This paper is only available as a PDF. To read, Please Download here.

      Article info

      Identification

      DOI: https://doi.org/10.1016/S2666-1683(20)35358-1

      Copyright

      © 2020 European Association of Urology. Published by Elsevier Inc.

      User license

      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0) |
      How you can reuse Information Icon
      Creative Commons Attribution – NonCommercial – NoDerivs (CC BY-NC-ND 4.0)

      Permitted

      For non-commercial purposes:

      • Read, print & download
      • Redistribute or republish the final article
      • Text & data mine
      • Translate the article (private use only, not for distribution)
      • Reuse portions or extracts from the article in other works

      Not Permitted

      • Sell or re-use for commercial purposes
      • Distribute translations or adaptations of the article

      Elsevier's open access license policy

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX